Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PYCR1 | P32322 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3620117 | 0.81 | KDM4E (0.56) | MEN1KMT2AKDM4EALDH1A1PYCR1 | |
| SCHEMBL18776435 | 0.74 | PIK3CD (0.33) | MEN1KMT2A | |
| SCHEMBL1239426 | 0.74 | KDM4E (0.59) | KDM4EALDH1A1PYCR1TDP1GLA | |
| SCHEMBL21962259 | 0.72 | PYCR1 (0.53) | MEN1KMT2AKDM4EALDH1A1PYCR1 | |
| SCHEMBL2059035 | 0.71 | PYCR1 (0.50) | MEN1KMT2AKDM4EALDH1A1PYCR1 | |
| SCHEMBL12570492 | 0.69 | MEN1 (0.36) | MEN1KMT2A | |
| SCHEMBL3574502 | 0.69 | HDAC1 (0.52) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL14376814 | 0.69 | SLC6A4 (0.48) | MEN1KMT2A | |
| SCHEMBL629044 | 0.68 | MAPT (0.55) | MEN1KMT2AALDH1A1TDP1MAPT | |
| SCHEMBL3746659 | 0.68 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SW) | 2010-02-04 | — | — | US | disclosed |
| US-7572826-B2 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1583755-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063186-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | MEN1 4599/4885KMT2A 421/4885KDM4E 333/4885 |
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | NFKBIA, RELA, IKBKE | MEN1 4599/4885KMT2A 421/4885KDM4E 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.